We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for AstraZeneca’s Fasenra (benralizumab) to treat eosinophilic granulomatosis with polyangiitis (EGPA).....
FDA expanded the approved use of Nucala to treat adult patients with eosinophilic granulomatosis with polyangiitis , a rare autoimmune disease that causes vasculitis, an inflammation in the wall of blood vessels of the body